in early responders opsonized B cells block the macrophage system, a mechanism that reminds the mechanism of Fc receptor (FcR) blockade by opsonized red cells following anti-D immunoglobulin treatment.\(^4\) The decreased production of antiplatelet antibodies accounts for the late and sustained response. In late responders, the FcR blockade effect for some reason does not work, and we only see the late response.

In conclusion, our results confirm that rituximab is an active agent in patients with chronic ITP and that the side effects of this treatment are of mild entity. Contrary to our preliminary observations,\(^1\) responses can be expected not only early during treatment but also up to 6 weeks after the last rituximab infusion. Several issues about this agent, such as the optimum dose and treatment schedule, the exact mechanisms of action, and long-term side effects, are the objectives of current investigations.

**To the editor:**  

**Mouse surviving solely on human erythropoietin receptor (EpoR): model of human EpoR-linked disease**

Mouse models of human diseases have contributed immensely to our understanding of the function of genes and their mutations and to the disease phenotype. In some cases, the compatibility of human and mouse signal transduction interactions allows replacement of the mouse genes with their human counterparts. In those cases, disease-causing mutations from patients can be introduced into the mouse germ line allowing direct testing of the gene defect in vivo. Different genetic approaches have been used to create animal models of human diseases caused by gain-of-function mutations. Human transgenics have been bred onto its mouse homologue knock-out background,\(^1\) or the human gene has been used to directly replace its murine homologue (ie, knocked-in into the mouse gene locus).\(^2\) A necessary assumption of a functional mutant human gene in the mouse environment is the full compatibility of these genes in both species.

Using the transgenic approach, Yu et al\(^3\) have recently shown that the human erythropoietin receptor (EpoR) can rescue erythropoiesis and all other developmental defects associated with the mouse EpoR deficiency. The 80-kb human EpoR transgene recapitulated EpoR expression not only in hematopoietic tissues but also in other tissues known to express EpoR. The human EpoR–rescued mice exhibited normal hematologic parameters (including hemoglobin and normal numbers of erythroid progenitors in the bone marrow. However, Yu et al\(^3\)) also concluded that mouse erythropoietin (Epo) and human EpoR are fully compatible in vivo and that the human erythropoietin receptor (EpoR) can rescue erythropoiesis not only in hematopoietic tissues but also in other tissues known to express Epo.

Interestingly, another animal model of truncated EpoR without apparent polycythemic phenotype in adults and with comparable in vitro responses of wild-type and mutant erythroid progenitors to Epo was later published by Zang et al.\(^5\) The reason for this discrepancy is not clear; in both cases the resulting truncated EpoR contained one tyrosine. However, it is possible that the mutant human EpoR-linked disease that we knocked-in into the mouse EpoR locus was cloned from a patient with primary familial and congenital polycythemia (PFCP).\(^6\) We have shown that mice heterozygous or homozygous for the truncated gain-of-function human EpoR were polycythemic and their erythroid progenitors had increased in vitro sensitivity to both mouse and human Epo.\(^2\) Interestingly, another animal model of truncated EpoR without apparent polycythemic phenotype in adults and with comparable in vitro responses of wild-type and mutant erythroid progenitors to Epo was later published by Zang et al.\(^6\) The reason for this discrepancy is not clear; in both cases the resulting truncated EpoR contained one tyrosine. However, it is possible that the mutant...
EpoR isolated from the subject with PFCP has different functional properties than the artificially truncated mouse EpoR used by Zang et al.⁶ The levels of expression of the mutant EpoR were comparable to the wild-type mouse EpoR in both studies; however, in our model the level of expression was achieved only after removal of the neomycin (neo)–selectable marker by crossing the mice to cre-transgenic mice (Figure 1). The animals reported by Zang et al⁶ had the neo gene retained in the EpoR locus, albeit driven by a different promoter than that used by us.

While these data indicate that the differences between mouse and human cellular environment exist, they do not undermine the usefulness of the mouse models of human diseases. Our objective, a comparison of disabled and reactivated gain-of-function Epo/ EpoR signaling in different tissues through cre-mediated recombination, should help our understanding of the role of Epo signaling in nonerythroid tissues and elucidate the increased risk of cardiovascular disease in PFCP.

Vladimir Divoky and Josef T. Prchal

Response:

Equivalence of mouse and human erythropoietin/erythropoietin receptor signaling

Divoky et al have produced mice expressing the full-length and truncated human EPOR that exhibit mild anemia and polycythemia respectively.¹ Based on comparisons with mice expressing endogenous erythropoietin receptor (Epor) or a truncated mouse Epor,² they suggest that mouse and human EPO/EPOR signaling are compatible but are different quantitatively in their interactions. Such differences would have important implications for mouse models of human diseases based on human EPO expression and signaling.

An explanation for differences in mice expressing human EPO may not reflect different signaling interactions between human and mouse EPO/EPOR but rather the levels of EPO expression. We found that a human EPO transgene (80 kb) with expression comparable to the endogenous mouse Epor at all phases of development (yolk sac, fetal liver, and adult spleen and bone marrow)³ quantitatively rescues the mouse Epor null phenotype.⁴ Hemoglobin, hematopoietic progenitors (erythroid burst-forming unit, granulocyte macrophage colony-forming unit, granulocyte-erythrocyte-megakaryocyte-macrophage colony-forming unit), and response to anemic stress (reticulocyte count and hematocrit) are similar to control mice. No differences in spleen size were noted, and all animals exhibit an increase in spleen size upon phenyldrazine treatment. Although higher levels of Epo induction were detected in the mEpor⁻/⁻ hEpor⁺ mice after phenyldrazine treatment (2.5 that of control animals), hematopoietic parameters suggest that expression of this human EPO transgene behaves largely analogous to endogenous mouse Epor. This transgene also corrects the increased apoptosis associated with mEpor⁻/⁻ fetal brain and heart development.⁵

The construction of the human EPO gene by Divoky et al¹ differ markedly from our human EPO transgene. We previously carried out careful analysis of the human EPO proximal region and found that while much of the transcription activity is contained in a 15–base pair (bp) 5’ proximal promoter fragment, contributions can be seen from the more distal flanking regions.⁶ This is also observed in reporter gene experiments in transgenic mice for promoter fragments extending to 150-bp 5’ and 1778-bp 5’ (Z. Y. Liu, C. Liu, and C. T. Noguchi, unpublished data, 2002). Additional flanking sequences appear to be required to provide a high level of human EPO expression in vivo. For the intact human EPO transgene, we made more than 15 transgenic lines with low copy number using 3 different genomic fragments. The construct extending only 2 kb 5’ provides an appropriate but low level of tissue-specific EPO expression, about an order of magnitude lower than the endogenous mEpor.⁷ A significantly higher level of expression on the order of the endogenous gene is observed with 2 other constructs containing longer 5’ regions. Both of these human EPO gene fragments are able to rescue the mEpor⁻¹⁻ phenotype, and the 80-kb human EPO fragment was chosen for further study.³ This transgene shows appropriate expression in a variety of tissues quantitatively comparable to endogenous mouse Epor, particularly in hematopoietic tissue.

Both the mouse and human proximal promoters contain requisite GATA-1 and SP1 binding sites and are homologous in this region.⁵,⁸ However, homology of the 5’ flanking region does not extend much beyond -60 bp 5’.⁹ To target the mouse locus, Divoky et al used a human EPO gene fragment (DraI) extending to -550 bp 5’ fused to the 5’ flanking mouse Epor region at -300 bp (Nael).³ This construct retains a species-specific upstream repetitive element that inhibits transcription of the mouse Epor,¹⁰ and the 550 bp proximal promoter fragment for human EpoR is considerably less than the 1778 bp fragment that resulted in the low level of transgene expression in vivo.³ Based on our studies of human EPO gene expression, the differences in the 5’ region flanking the human EPO genes used to produce the 2 mouse models are significant. Variations in human EPO expression due to differences in background strain or site of gene integration are also possible. Careful quantification of EPO during development and in adult mice would clarify if a lower level of human EPO expression in mice produced by Divoky et al accounts for the associated mild anemia without invoking differences between mouse and human EPO signaling.

References

As another piece of evidence that mouse and human EPO/EPOR signaling are different, Divoky and Prchal point to the production of mice expressing truncated Epor with only a single cytoplasmic tyrosine at 343,1,2 After initial reports of a negative regulatory domain in the cytoplasmic tail of mouse Epor11 and human EPOR,12 other truncated deletions in human EPOR have been associated with polycythemia including the mutation constructed by Divoky et al.1 These mice express human EpoR with a truncated deletion just before tyrosine 410 and exhibit a polycythemia phenotype as predicted from the human condition. Interestingly, in addition to direct alteration of EPO signaling, increased cell-surface expression via posttranslational mechanism(s) has been suggested for a truncated EPOR associated primary familial and congenital polycythemia.13 Other mice expressing a truncated mouse EpoR were constructed by altering the endogenous Epor sequence 3′ of the HindIII site resulting in a truncated mouse Epor with a single cytoplasmic tyrosine that is about 2 dozen amino acids shorter than the Divoky and Prchal deletion.12 These mice exhibit largely constitutive erythropoiesis and are not polycythemic. While it is possible that these differences may be inherent in mouse versus human EPOR, variation in erythrocytosis may also result from the extent or level of expression of the truncations.

Recapitulation of the human phenotype with the truncated human EPOR by Divoky et al1 confirms the similarity of EPO/EPOR signaling in mouse and human and the potential for using mouse models to understand EPO/EPOR interactions. The differences noted here among the EPOR mouse models illustrate the advantages and limitations of manipulating the mouse genome to alter phenotypic expression. When comparing model systems, careful analysis of gene construction in vivo, mouse strains, and possible integration sites are necessary to ensure comparable expression and analogous gene products. Note that while the original targeting construct for human EPOR by Divoky and Prchal was active in vitro, it was necessary to remove the neomycin (neo)-selectable marker from human Epor intron 6 to obtain expression in vivo, although the neo gene remains 3’ flanking the endogenous mouse Epor produced by Zang et al.12 Variation in gene expression can become significant, particularly when the differences are small. While human and mouse EPO/EPOR signaling may not be equivalent, we do not see any evidence that they are significantly different in our EPO/EPOR animal model.

Xiaobing Yu and Constance Tom Noguchi
Correspondence: Constance Tom Noguchi, Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Dr MSC-1822, Bethesda, MD 20892-1822.

References

To the editor:

CD34 stem cell dose and development of extensive chronic graft-versus-host disease

Granulocyte colony-stimulating factor (G-CSF)–mobilized peripheral blood mononuclear cells (G-PBMCs) are increasingly used as a stem cell source for allogeneic transplantation. The in vivo administration of G-CSF to the donor results in an increase of circulating CD34+ hematopoietic progenitor cells, which are responsible for engraftment after myeloablative therapy.

In a recent report by Zaucha et al.,1 an association between the CD34 cell dose in G-PBMCs collected from human leukocyte antigen (HLA)–identical siblings and the development of extensive chronic graft-versus-host disease (cGvHD) is shown. The number of CD3 T lymphocytes or CD14 monocytes in the graft were not significantly associated with extensive cGvHD. Therefore, the authors concluded that increasing the CD34 cell number in G-PBMC products may be counterproductive and suggest limiting the number of CD34 cells in the unmodified G-PBMC grafts.

Rather than using unmodified G-PBMC grafts, we have transplanted highly purified G-CSF–mobilized peripheral CD34 stem cells from HLA-matched unrelated2 and HLA-mismatched haploidentical donors3 in 76 pediatric patients with malignant and nonmalignant diseases. The CD34 cells were purified to a median purity of at least 98% and transplanted without any posttransplantation GvHD prophylaxis. The median number of transplanted CD34 stem cells was 12.1 × 10^6/kg recipient body weight with a wide range of 1 to 54.6 × 10^6/kg. The median number of cotransplanted CD3 T lymphocytes was 7.6 × 10^6/kg (range, 0.5-130 × 10^6/kg). The median follow-up time for our patients is 2.9 years (range, 0.9 to 10.3 years). The number of CD3 T lymphocytes or CD14 monocytes in the G-PBMC grafts.

In contrast to the study by Zaucha et al, we have not seen any correlation between the number of transplanted CD34 stem cells and the development of extensive chronic GvHD. A transient,
Mouse surviving solely on human erythropoietin receptor (EpoR): model of human EpoR-linked disease

Vladimir Divoky and Josef T. Prchal